Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 9/20 | 0.66 |
| ▸ | FADS1 | O60427 | 3/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | F10 | P00742 | 1/20 | 0.51 |
| ▸ | BPTF | Q12830 | 1/20 | 0.50 |
| ▸ | CALML3 | P27482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2896939 | 1.00 | GRM2 (0.66) | GRM2FADS1MAOAMAOBF10 | |
| SCHEMBL27915892 | 0.86 | GRM2 (0.66) | GRM2FADS1MAOAMAOBCALML3 | |
| SCHEMBL1557298 | 0.86 | MAOA (0.71) | GRM2FADS1MAOAMAOBCALML3 | |
| SCHEMBL14769778 | 0.86 | GRM2 (0.73) | GRM2FADS1MAOAMAOB | |
| SCHEMBL1032517 | 0.86 | MAOA (0.71) | GRM2FADS1MAOAMAOBCALML3 | |
| SCHEMBL30063909 | 0.86 | MAOA (0.71) | GRM2FADS1MAOAMAOBCALML3 | |
| SCHEMBL3087781 | 0.86 | MAOA (0.71) | GRM2FADS1MAOAMAOBCALML3 | |
| SCHEMBL2896810 | 0.85 | F10 (0.52) | GRM2FADS1MAOAMAOBF10 | |
| SCHEMBL2901464 | 0.85 | F10 (0.52) | GRM2FADS1MAOAMAOBF10 | |
| SCHEMBL5618040 | 0.84 | F10 (0.50) | GRM2FADS1MAOAMAOBF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603904-A1 | ANTIBACTERIAL 1, 3- OXAZOLIDIN -2- ONE DERIVATIVES | AstraZeneca AB (SE) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004083205-A1 | ANTIBACTERIAL 1, 3- OXAZOLIDIN -2- ONE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-09-30 | — | — | WO | disclosed |
| US-6689779-B2 | PYRIDINE OR PYRIMIDINE SUBSTITUTED; ANTIBACTERIAL ACTIVITY; LOW TOXICITY | DONG A PHARM. CO., LTD. (KR) | 2004-02-10 | — | — | US | disclosed |
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | DONG A PHARM. CO., LTD. (KR) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | OXA1L, ODC1, PDCD4 | GRM2 4033/4885FADS1 3702/4885MAOA 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.